A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT03431350 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG: Niraparib 200 mg
DRUG: Cetrelimab 240 mg
DRUG: Cetrelimab 480 mg
DRUG: Abiraterone acetate 1000 mg
DRUG: Prednisone 5 mg

Sponsor

Janssen Research & Development, LLC